Amedeo Smart

Free Medical Literature Service


 

Amedeo

Prostate Cancer

  Free Subscription

Articles published in
Eur Radiol
    December 2024
  1. DIAS AB, Woo S, Leni R, Rajwa P, et al
    Is MRI ready to replace biopsy during active surveillance?
    Eur Radiol. 2024;34:7716-7727.
    >> Share

  2. BOZGO V, Roest C, van Oort I, Yakar D, et al
    Prostate MRI and artificial intelligence during active surveillance: should we jump on the bandwagon?
    Eur Radiol. 2024;34:7698-7704.
    >> Share

    November 2024
  3. RATA M, Orton MR, Tunariu N, Curcean A, et al
    Repeatability of quantitative MR fingerprinting for T(1) and T(2) measurements of metastatic bone in prostate cancer patients.
    Eur Radiol. 2024 Nov 6. doi: 10.1007/s00330-024-11162.
    >> Share

  4. DE ROOIJ M, Allen C, Twilt JJ, Thijssen LCP, et al
    PI-QUAL version 2: an update of a standardised scoring system for the assessment of image quality of prostate MRI.
    Eur Radiol. 2024;34:7068-7079.
    >> Share

  5. PONSIGLIONE A, Brembilla G, Cuocolo R, Gutierrez P, et al
    ESR Essentials: using the right scoring system in prostate MRI-practice recommendations by ESUR.
    Eur Radiol. 2024;34:7481-7491.
    >> Share

  6. VAN LOHUIZEN Q, Roest C, Simonis FFJ, Fransen SJ, et al
    Assessing deep learning reconstruction for faster prostate MRI: visual vs. diagnostic performance metrics.
    Eur Radiol. 2024;34:7364-7372.
    >> Share

    October 2024
  7. HAMM CA, Baumgartner GL, Padhani AR, Frobose KP, et al
    Reduction of false positives using zone-specific prostate-specific antigen density for prostate MRI-based biopsy decision strategies.
    Eur Radiol. 2024;34:6229-6240.
    >> Share

  8. MARVASO G, Isaksson LJ, Zaffaroni M, Vincini MG, et al
    Can we predict pathology without surgery? Weighing the added value of multiparametric MRI and whole prostate radiomics in integrative machine learning models.
    Eur Radiol. 2024;34:6241-6253.
    >> Share

    September 2024
  9. BOSCHHEIDGEN M, Schimmoller L, Radtke JP, Kastl R, et al
    MRI characteristics predict risk of pathological upgrade in patients with ISUP grade group 1 prostate cancer.
    Eur Radiol. 2024 Sep 13. doi: 10.1007/s00330-024-11062.
    >> Share

    August 2024
  10. FRANSEN SJ, Kwee TC, Rouw D, Roest C, et al
    Patient perspectives on the use of artificial intelligence in prostate cancer diagnosis on MRI.
    Eur Radiol. 2024 Aug 14. doi: 10.1007/s00330-024-11012.
    >> Share

  11. ISRAEL B
    From data to decisions: deep learning is shaping prostate cancer diagnostics.
    Eur Radiol. 2024 Aug 2. doi: 10.1007/s00330-024-10997.
    >> Share

    July 2024
  12. AGROTIS G, Pooch E, Abdelatty M, Benson S, et al
    Diagnostic performance of ADC and ADCratio in MRI-based prostate cancer assessment: A systematic review and meta-analysis.
    Eur Radiol. 2024 Jul 12. doi: 10.1007/s00330-024-10890.
    >> Share

  13. SCHRADER A, Netzer N, Hielscher T, Gortz M, et al
    Prostate cancer risk assessment and avoidance of prostate biopsies using fully automatic deep learning in prostate MRI: comparison to PI-RADS and integration with clinical data in nomograms.
    Eur Radiol. 2024 Jul 2. doi: 10.1007/s00330-024-10818.
    >> Share

  14. STANZIONE A, Lee KL, Sanmugalingam N, Rajendran I, et al
    Expect the unexpected: investigating discordant prostate MRI and biopsy results.
    Eur Radiol. 2024;34:4810-4820.
    >> Share

  15. LANGKILDE F, Masaba P, Edenbrandt L, Gren M, et al
    Manual prostate MRI segmentation by readers with different experience: a study of the learning progress.
    Eur Radiol. 2024;34:4801-4809.
    >> Share

    June 2024
  16. PADHANI AR, Tunariu N, Perez-Lopez R, Tombal B, et al
    Evaluating prostate cancer bone metastases response with whole-body MRI: What we know and still need to know.
    Eur Radiol. 2024 Jun 20. doi: 10.1007/s00330-024-10864.
    >> Share

  17. NAKAI H, Suman G, Adamo DA, Navin PJ, et al
    Natural language processing pipeline to extract prostate cancer-related information from clinical notes.
    Eur Radiol. 2024 Jun 6. doi: 10.1007/s00330-024-10812.
    >> Share

  18. PONSIGLIONE A, Gambardella M, Stanzione A, Green R, et al
    Radiomics for the identification of extraprostatic extension with prostate MRI: a systematic review and meta-analysis.
    Eur Radiol. 2024;34:3981-3991.
    >> Share

    May 2024
  19. OERTHER B, Engel H, Nedelcu A, Strecker R, et al
    Performance of an ultra-fast deep-learning accelerated MRI screening protocol for prostate cancer compared to a standard multiparametric protocol.
    Eur Radiol. 2024 May 23. doi: 10.1007/s00330-024-10776.
    >> Share

  20. BREMBILLA G, Giganti F
    Improving image quality in prostate MRI: the time is now.
    Eur Radiol. 2024;34:3385-3386.
    >> Share

  21. NAKAI H, Takahashi H, Adamo DA, LeGout JD, et al
    Decreased prostate MRI cancer detection rate due to moderate to severe susceptibility artifacts from hip prosthesis.
    Eur Radiol. 2024;34:3387-3399.
    >> Share

    April 2024
  22. MUGLIA VF
    Refining clinical decision strategies and prostate cancer detection through fine adjustments in the combination of PSA-derived parameters and MRI.
    Eur Radiol. 2024 Apr 29. doi: 10.1007/s00330-024-10734.
    >> Share

  23. CAGLIC I, Sushentsev N, Syer T, Lee KL, et al
    Biparametric MRI in prostate cancer during active surveillance: is it safe?
    Eur Radiol. 2024 Apr 24. doi: 10.1007/s00330-024-10770.
    >> Share

  24. BOELLAARD TN, van Dijk-de Haan MC, Heijmink SWTPJ, Tillier CN, et al
    Membranous urethral length measurement on preoperative MRI to predict incontinence after radical prostatectomy: a literature review towards a proposal for measurement standardization.
    Eur Radiol. 2024;34:2621-2640.
    >> Share

    March 2024
  25. GIROMETTI R, Giganti F
    Active surveillance of prostate cancer: MRI and beyond.
    Eur Radiol. 2024 Mar 28. doi: 10.1007/s00330-024-10717.
    >> Share

    February 2024
  26. PADHANI AR, Godtman RA, Schoots IG
    Key learning on the promise and limitations of MRI in prostate cancer screening.
    Eur Radiol. 2024 Feb 5. doi: 10.1007/s00330-024-10626.
    >> Share

    January 2024
  27. MAZZETTI S, Defeudis A, Nicoletti G, Chiorino G, et al
    Development and validation of a clinical decision support system based on PSA, microRNAs, and MRI for the detection of prostate cancer.
    Eur Radiol. 2024 Jan 4. doi: 10.1007/s00330-023-10542.
    >> Share

  28. PANEBIANCO V
    Prostate cancer imaging for primary detection: PSMA-PET/CT vs MRI. All that glitters is not gold.
    Eur Radiol. 2024 Jan 2. doi: 10.1007/s00330-023-10547.
    >> Share

    December 2023
  29. EVANGELISTA L, Filippi L
    Structured reporting in prostate cancer: the revolution of quality in nuclear medicine scan interpretation.
    Eur Radiol. 2023 Dec 20. doi: 10.1007/s00330-023-10507.
    >> Share

  30. NOTO B, Eveslage M, Auf der Springe K, Exler A, et al
    Robustness of apparent diffusion coefficient-based lymph node classification for diagnosis of prostate cancer metastasis.
    Eur Radiol. 2023 Dec 15. doi: 10.1007/s00330-023-10406.
    >> Share

  31. JANNUSCH K, Bruckmann NM, Morawitz J, Boschheidgen M, et al
    Recurrent prostate cancer: combined role for MRI and PSMA-PET in (68)Ga-PSMA-11 PET/MRI.
    Eur Radiol. 2023 Dec 1. doi: 10.1007/s00330-023-10442.
    >> Share

  32. ROUVIERE O
    Contrast-medium administration for prostate MRI can be abandoned: no(t so simple)!
    Eur Radiol. 2023;33:8415-8416.
    >> Share

  33. ASBACH P
    Contrast-medium administration for prostate MRI: yes! Contrast-medium administration can be abandoned.
    Eur Radiol. 2023;33:8413-8414.
    >> Share

    November 2023
  34. MA J, Yang Q, Ye X, Xu W, et al
    Head-to-head comparison of prostate-specific membrane antigen PET and multiparametric MRI in the diagnosis of pretreatment patients with prostate cancer: a meta-analysis.
    Eur Radiol. 2023 Nov 20. doi: 10.1007/s00330-023-10436.
    >> Share

  35. NETZER N, Eith C, Bethge O, Hielscher T, et al
    Application of a validated prostate MRI deep learning system to independent same-vendor multi-institutional data: demonstration of transferability.
    Eur Radiol. 2023;33:7463-7476.
    >> Share

    September 2023
  36. COHEN D, Hazut Krauthammer S, Fahoum I, Kesler M, et al
    PET radiotracers for whole-body in vivo molecular imaging of prostatic neuroendocrine malignancies.
    Eur Radiol. 2023;33:6502-6512.
    >> Share

    August 2023
  37. FRANCO PN, Frade-Santos S, Garcia-Baizan A, Paredes-Velazquez L, et al
    An MRI assessment of prostate cancer local recurrence using the PI-RR system: diagnostic accuracy, inter-observer reliability among readers with variable experience, and correlation with PSA values.
    Eur Radiol. 2023 Aug 30. doi: 10.1007/s00330-023-09949.
    >> Share

  38. GRAWE F, Blom F, Winkelmann M, Burgard C, et al
    Reliability and practicability of PSMA-RADS 1.0 for structured reporting of PSMA-PET/CT scans in prostate cancer patients.
    Eur Radiol. 2023 Aug 25. doi: 10.1007/s00330-023-10083.
    >> Share

  39. DONNERS R, Tunariu N, Tovey H, Hall E, et al
    The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases.
    Eur Radiol. 2023 Aug 24. doi: 10.1007/s00330-023-10172.
    >> Share

  40. MESSINA E, La Torre G, Pecoraro M, Pisciotti ML, et al
    Design of a magnetic resonance imaging-based screening program for early diagnosis of prostate cancer: preliminary results of a randomized controlled trial-Prostate Cancer Secondary Screening in Sapienza (PROSA).
    Eur Radiol. 2023 Aug 10. doi: 10.1007/s00330-023-10019.
    >> Share

  41. MESSINA E, Pecoraro M, Laschena L, Bicchetti M, et al
    Low cancer yield in PI-RADS 3 upgraded to 4 by dynamic contrast-enhanced MRI: is it time to reconsider scoring categorization?
    Eur Radiol. 2023;33:5828-5839.
    >> Share

    July 2023
  42. NHAT TO MN, Kwak JT
    Retraction Note: Biparametric MR signal characteristics can predict histopathological measures of prostate cancer.
    Eur Radiol. 2023 Jul 31. doi: 10.1007/s00330-023-09887.
    >> Share

  43. LIU G, Pan S, Zhao R, Zhou H, et al
    The added value of AI-based computer-aided diagnosis in classification of cancer at prostate MRI.
    Eur Radiol. 2023;33:5118-5130.
    >> Share

  44. JIMENEZ-PASTOR A, Lopez-Gonzalez R, Fos-Guarinos B, Garcia-Castro F, et al
    Automated prostate multi-regional segmentation in magnetic resonance using fully convolutional neural networks.
    Eur Radiol. 2023;33:5087-5096.
    >> Share

    May 2023
  45. ASBACH P, Padhani AR
    Are upgraded DCE-positive PI-RADS 3 lesions truly suspicious for clinically significant prostate cancer?
    Eur Radiol. 2023 May 8. doi: 10.1007/s00330-023-09711.
    >> Share

  46. PADHANI AR, Schoots IG
    Prostate cancer screening-stepping forward with MRI.
    Eur Radiol. 2023 May 8. doi: 10.1007/s00330-023-09673.
    >> Share

  47. PUECH P, Gutierrez PA, Berg-Logager V, Villeirs G, et al
    How should we prepare a generation of radiologists for MRI-based prostate cancer screening?
    Eur Radiol. 2023 May 6. doi: 10.1007/s00330-023-09680.
    >> Share

  48. DONSWIJK ML, Piek MW, Cheung Z, Wondergem M, et al
    Incidence of PSMA PET thyroid incidentaloma depends on analysis method and tracer.
    Eur Radiol. 2023;33:3377-3385.
    >> Share

  49. VEERMAN H, Hagens MJ, Hoeks CM, van der Poel HG, et al
    A standardized method to measure the membranous urethral length (MUL) on MRI of the prostate with high inter- and intra-observer agreement.
    Eur Radiol. 2023;33:3295-3302.
    >> Share

    April 2023
  50. MARTURANO F, Guglielmo P, Bettinelli A, Zattoni F, et al
    Role of radiomic analysis of [(18)F]fluoromethylcholine PET/CT in predicting biochemical recurrence in a cohort of intermediate and high risk prostate cancer patients at initial staging.
    Eur Radiol. 2023 Apr 20. doi: 10.1007/s00330-023-09642.
    >> Share

  51. GAUR S
    Commentary: considering radiomics in the setting of prostate cancer active surveillance.
    Eur Radiol. 2023 Apr 18. doi: 10.1007/s00330-023-09634.
    >> Share

  52. SCHIRO S, Milanese G, Maddalo M, Ziglioli F, et al
    MR-based simplified extraprostatic extension evaluation: comparison of performances of different predictive models.
    Eur Radiol. 2023;33:2975-2984.
    >> Share

  53. THIMANSSON E, Bengtsson J, Baubeta E, Engman J, et al
    Deep learning algorithm performs similarly to radiologists in the assessment of prostate volume on MRI.
    Eur Radiol. 2023;33:2519-2528.
    >> Share

  54. PARK MY, Park KJ, Kim MH, Kim JK, et al
    Focal nodular enhancement on DCE MRI of the prostatectomy bed: radiologic-pathologic correlations and prognostic value.
    Eur Radiol. 2023;33:2985-2994.
    >> Share

    March 2023
  55. QIN C, Goldberg O, Kakar G, Wan S, et al
    MRI fat fraction imaging of nodal and bone metastases in prostate cancer.
    Eur Radiol. 2023 Mar 16. doi: 10.1007/s00330-023-09527.
    >> Share

  56. BAUCKNEHT M, Miceli A, Signori A, Albano D, et al
    Combined forced diuresis and late acquisition on [(68)Ga]Ga-PSMA-11 PET/CT for biochemical recurrent prostate cancer: a clinical practice-oriented study.
    Eur Radiol. 2023 Mar 9. doi: 10.1007/s00330-023-09516.
    >> Share

    February 2023
  57. SUSHENTSEV N, Rundo L, Abrego L, Li Z, et al
    Time series radiomics for the prediction of prostate cancer progression in patients on active surveillance.
    Eur Radiol. 2023 Feb 7. doi: 10.1007/s00330-023-09438.
    >> Share

    January 2023
  58. LABUS S, Altmann MM, Huisman H, Tong A, et al
    A concurrent, deep learning-based computer-aided detection system for prostate multiparametric MRI: a performance study involving experienced and less-experienced radiologists.
    Eur Radiol. 2023;33:64-76.
    >> Share

  59. GIGANTI F, Cole AP, Fennessy FM, Clinton T, et al
    Promoting the use of the PI-QUAL score for prostate MRI quality: results from the ESOR Nicholas Gourtsoyiannis teaching fellowship.
    Eur Radiol. 2023;33:461-471.
    >> Share

    November 2022
  60. DENIFFEL D, Perlis N, Ghai S, Girgis S, et al
    Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy.
    Eur Radiol. 2022;32:7544-7554.
    >> Share

  61. CORNUD F, Lefevre A, Camparo P, Barat M, et al
    Post-MRI transrectal micro-ultrasonography of transition zone PI-RADS > 2 lesions for biopsy guidance.
    Eur Radiol. 2022;32:7504-7512.
    >> Share

    October 2022
  62. LIAO Z, Liu G, Ming B, Ma C, et al
    Evaluating prostate cancer bone metastasis using accelerated whole-body isotropic 3D T1-weighted Dixon MRI with compressed SENSE: a feasibility study.
    Eur Radiol. 2022 Oct 21. pii: 10.1007/s00330-022-09181.
    >> Share

    September 2022
  63. GANDAGLIA G, Giannarini G, Stabile A, Montorsi F, et al
    Should we combine systematic with MRI-targeted biopsy? Implications for the management of patients with prostate cancer.
    Eur Radiol. 2022 Sep 15. pii: 10.1007/s00330-022-09096.
    >> Share

  64. PANEBIANCO V, Turkbey B
    Magnetic resonance imaging for prostate cancer recurrence: it's time for precision diagnostic with Prostate Imaging for Recurrence Reporting (PI-RR) score.
    Eur Radiol. 2022 Sep 1. pii: 10.1007/s00330-022-09095.
    >> Share

    August 2022
  65. ROEST C, Kwee TC, Saha A, Futterer JJ, et al
    AI-assisted biparametric MRI surveillance of prostate cancer: feasibility study.
    Eur Radiol. 2022 Aug 12. pii: 10.1007/s00330-022-09032.
    >> Share

  66. RUD E, Noor D, Galtung KF, Ottosson F, et al
    Validating the screening criteria for bone metastases in treatment-naive unfavorable intermediate and high-risk prostate cancer - the prevalence and location of bone- and lymph node metastases.
    Eur Radiol. 2022 Aug 8. pii: 10.1007/s00330-022-08945.
    >> Share

    July 2022
  67. DONNERS R, Fotiadis N, Figueiredo I, Blackledge M, et al
    Optimising CT-guided biopsies of sclerotic bone lesions in cancer patients.
    Eur Radiol. 2022 Jul 26. pii: 10.1007/s00330-022-09011.
    >> Share

  68. BEHESHTI M, Taimen P, Kemppainen J, Jambor I, et al
    Value of (68)Ga-labeled bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [(18)F]fluoromethylcholine PET-CT and multiparametric MRI-a phase I/II study.
    Eur Radiol. 2022 Jul 21. pii: 10.1007/s00330-022-08982.
    >> Share

  69. HAMZAOUI D, Montagne S, Granger B, Allera A, et al
    Prostate volume prediction on MRI: tools, accuracy and variability.
    Eur Radiol. 2022;32:4931-4941.
    >> Share

    June 2022
  70. SUSHENTSEV N, McLean MA, Warren AY, Brodie C, et al
    The potential of hyperpolarised (13)C-MRI to target glycolytic tumour core in prostate cancer.
    Eur Radiol. 2022 Jun 22. pii: 10.1007/s00330-022-08929.
    >> Share

    May 2022
  71. TO MNN, Kwak JT
    Biparametric MR signal characteristics can predict histopathological measures of prostate cancer.
    Eur Radiol. 2022 May 4. pii: 10.1007/s00330-022-08808.
    >> Share

    April 2022
  72. MA W, Mao J, Yang J, Wang T, et al
    Comparing the diagnostic performance of radiotracers in prostate cancer biochemical recurrence: a systematic review and meta-analysis.
    Eur Radiol. 2022 Apr 29. pii: 10.1007/s00330-022-08802.
    >> Share

  73. BLEKER J, Kwee TC, Rouw D, Roest C, et al
    A deep learning masked segmentation alternative to manual segmentation in biparametric MRI prostate cancer radiomics.
    Eur Radiol. 2022 Apr 14. pii: 10.1007/s00330-022-08712.
    >> Share

  74. PADHANI AR, Haider MA, Rouviere O
    Balancing the benefits and harms of MRI-directed biopsy pathways.
    Eur Radiol. 2022;32:2326-2329.
    >> Share

  75. MICHALLEK F, Huisman H, Hamm B, Elezkurtaj S, et al
    Accuracy of fractal analysis and PI-RADS assessment of prostate magnetic resonance imaging for prediction of cancer grade groups: a clinical validation study.
    Eur Radiol. 2022;32:2372-2383.
    >> Share

    March 2022
  76. GATTI M, Faletti R, Gentile F, Soncin E, et al
    mEPE-score: a comprehensive grading system for predicting pathologic extraprostatic extension of prostate cancer at multiparametric magnetic resonance imaging.
    Eur Radiol. 2022 Mar 15. pii: 10.1007/s00330-022-08595.
    >> Share

  77. ZHENG H, Miao Q, Liu Y, Mirak SA, et al
    Multiparametric MRI-based radiomics model to predict pelvic lymph node invasion for patients with prostate cancer.
    Eur Radiol. 2022 Mar 3. pii: 10.1007/s00330-022-08625.
    >> Share

    February 2022
  78. PENZKOFER T, Padhani AR, Turkbey B, Ahmed HU, et al
    Assessing the clinical performance of artificial intelligence software for prostate cancer detection on MRI.
    Eur Radiol. 2022 Feb 23. pii: 10.1007/s00330-022-08609.
    >> Share

  79. DE ROOIJ M, Barentsz JO
    PI-QUAL v.1: the first step towards good-quality prostate MRI.
    Eur Radiol. 2022;32:876-878.
    >> Share

  80. GIGANTI F, Dinneen E, Kasivisvanathan V, Haider A, et al
    Inter-reader agreement of the PI-QUAL score for prostate MRI quality in the NeuroSAFE PROOF trial.
    Eur Radiol. 2022;32:879-889.
    >> Share

    January 2022
  81. BITTENCOURT LK, Guricova K, Zucker I, Durieux JC, et al
    Risk-based MRI-directed diagnostic pathway outperforms non-risk-based pathways in suspected prostate cancer biopsy-naive men: a large cohort validation study.
    Eur Radiol. 2022 Jan 14. pii: 10.1007/s00330-021-08407.
    >> Share

    December 2021
  82. MICHALLEK F, Huisman H, Hamm B, Elezkurtaj S, et al
    Prediction of prostate cancer grade using fractal analysis of perfusion MRI: retrospective proof-of-principle study.
    Eur Radiol. 2021 Dec 16. pii: 10.1007/s00330-021-08394.
    >> Share

    November 2021
  83. HOSSEINZADEH M, Saha A, Brand P, Slootweg I, et al
    Deep learning-assisted prostate cancer detection on bi-parametric MRI: minimum training data size requirements and effect of prior knowledge.
    Eur Radiol. 2021 Nov 16. pii: 10.1007/s00330-021-08320.
    >> Share

  84. BOSCHHEIDGEN M, Schimmoller L, Arsov C, Ziayee F, et al
    MRI grading for the prediction of prostate cancer aggressiveness.
    Eur Radiol. 2021 Nov 8. pii: 10.1007/s00330-021-08332.
    >> Share

    October 2021
  85. CUOCOLO R, Stanzione A, Faletti R, Gatti M, et al
    MRI index lesion radiomics and machine learning for detection of extraprostatic extension of disease: a multicenter study.
    Eur Radiol. 2021;31:7575-7583.
    >> Share

    September 2021
  86. HINZPETER R, Baumann L, Guggenberger R, Huellner M, et al
    Radiomics for detecting prostate cancer bone metastases invisible in CT: a proof-of-concept study.
    Eur Radiol. 2021 Sep 24. pii: 10.1007/s00330-021-08245.
    >> Share

  87. REISCHAUER C, Cancelli T, Malekzadeh S, Froehlich JM, et al
    How to improve image quality of DWI of the prostate-enema or catheter preparation?
    Eur Radiol. 2021;31:6708-6716.
    >> Share

    August 2021
  88. JENTJENS S, Mai C, Ahmadi Bidakhvidi N, De Coster L, et al
    Prospective comparison of simultaneous [(68)Ga]Ga-PSMA-11 PET/MR versus PET/CT in patients with biochemically recurrent prostate cancer.
    Eur Radiol. 2021 Aug 10. pii: 10.1007/s00330-021-08140.
    >> Share

    July 2021
  89. SUSHENTSEV N, Rundo L, Blyuss O, Nazarenko T, et al
    Comparative performance of MRI-derived PRECISE scores and delta-radiomics models for the prediction of prostate cancer progression in patients on active surveillance.
    Eur Radiol. 2021 Jul 13. pii: 10.1007/s00330-021-08151.
    >> Share

  90. BURA V, Caglic I, Snoj Z, Sushentsev N, et al
    MRI features of the normal prostatic peripheral zone: the relationship between age and signal heterogeneity on T2WI, DWI, and DCE sequences.
    Eur Radiol. 2021;31:4908-4917.
    >> Share

    May 2021
  91. PENZKOFER T, Padhani AR, Turkbey B, Haider MA, et al
    ESUR/ESUI position paper: developing artificial intelligence for precision diagnosis of prostate cancer using magnetic resonance imaging.
    Eur Radiol. 2021 May 15. pii: 10.1007/s00330-021-08021.
    >> Share

    April 2021
  92. WALLSTROM J, Geterud K, Kohestani K, Maier SE, et al
    Bi- or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Goteborg prostate cancer screening 2 trial.
    Eur Radiol. 2021 Apr 23. pii: 10.1007/s00330-021-07907.
    >> Share

  93. ALBERTS I, Hunermund JN, Sachpekidis C, Mingels C, et al
    The influence of digital PET/CT on diagnostic certainty and interrater reliability in [(68)Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer.
    Eur Radiol. 2021 Apr 15. pii: 10.1007/s00330-021-07870.
    >> Share

    January 2021
  94. STEINBERG RL, Rasmussen RG, Johnson BA, Ghandour R, et al
    Prospective performance of clear cell likelihood scores (ccLS) in renal masses evaluated with multiparametric magnetic resonance imaging.
    Eur Radiol. 2021;31:314-324.
    >> Share

  95. SCHELB P, Wang X, Radtke JP, Wiesenfarth M, et al
    Simulated clinical deployment of fully automatic deep learning for clinical prostate MRI assessment.
    Eur Radiol. 2021;31:302-313.
    >> Share

    November 2020
  96. DELLI PIZZI A, Mastrodicasa D, Marchioni M, Primiceri G, et al
    Bladder cancer: do we need contrast injection for MRI assessment of muscle invasion? A prospective multi-reader VI-RADS approach.
    Eur Radiol. 2020 Nov 19. pii: 10.1007/s00330-020-07473.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016